KOSDAQChemicals025320

Synopex

₩3,320▲ 4.24%2026-11-18 close
Market Cap
₩306.2B
Turnover
₩900M
Volume
280K
Shares out.
92.2M
PER
—
PBR
1.9×
EPS
-₩125
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Synopex: Testing New Businesses Beyond FPCB

Synopex is moving its weight from smartphone FPCB toward semiconductor chemical filters, dialysis products and EV FPCB. Its operating profit returned to the black in the third quarter of 2026, but net losses attributable to shareholders continued.

  1. 1

    FPCB generated 89.5% of total revenue in 2025, so results remain closely tied to smartphone demand.

  2. 2

    Operating profit fell to KRW 6.76 billion in 2025, declining for two straight years from the 2023 peak, and the operating margin dropped to 2.6%.

  3. 3

    Operating profit in the third quarter of 2026 turned positive at KRW 3.42 billion, while the net loss attributable to shareholders was KRW 4.4 billion, a swing into loss from a year earlier.

  4. 4

    New businesses include the dialysis HD product approval in August 2026, customer testing of 10-nanometer semiconductor chemical filters, and EV FPCB mass supply expected from 2027.

  5. 5

    The cumulative net loss attributable to shareholders over the last four quarters reached KRW 10.7 billion, so earnings-based multiples cannot be calculated.

02

Business structure

Synopex builds its business on membrane filter technology, spanning FPCB, semiconductor chemical filters, dialysis products and water treatment. FPCB is the core, generating 89.5% of total revenue in 2025, and about 90% of that FPCB revenue comes from smartphone products.

Reports describe Samsung Electronics smartphone FPCB as the dominant share of the revenue mix. The company was selected as an EV battery FPCB supplier to a global automaker and has completed a dedicated production plant, with customer sample testing nearing completion.

In July 2026 it announced a KRW 15 billion investment in EV FPCB module equipment. In semiconductor filters, it localized 10-nanometer chemical filters and is running quality tests for Samsung Electronics certification, while it announced development of 5-nanometer filters in February 2026.

In dialysis, its hemodialysis filters are supplied to 62 domestic hospitals and exports to Morocco have begun. Its water treatment business, built on the acquisition of Lotte Chemical's water treatment unit, brings MBR membrane patents and infrastructure. The company targets a 30% domestic market share by 2029.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩70.8B₩800M1.2%
2025Q4₩55.8B-₩6.5B−11.7%
2026Q1₩57.2B₩1.3B2.3%
2026Q2₩53.8B-₩1.9B−3.5%
2026Q3₩69.4B₩3.4B4.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩244.8B₩12.9B₩8.5B5.3%8.1%104.8%
2023₩262.2B₩24.2B₩14.6B9.2%10.9%50.1%
2024₩238.3B₩21.2B₩28.1B8.9%16.7%40.4%
2025₩261.5B₩6.8B₩7.4B2.6%4.3%51.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a disclosed annual basis, revenue rose from KRW 244.8 billion in 2022 to KRW 262.2 billion in 2023, a 7.1% increase, fell to KRW 238.3 billion in 2024, a 9.1% decrease, and recovered to KRW 261.5 billion in 2025, a 9.7% increase.

Operating profit peaked at KRW 24.2 billion in 2023, up 88.0%, then declined to KRW 21.2 billion in 2024 and KRW 6.76 billion in 2025, down 68.2%, so it fell for two consecutive years. The operating margin was 5.3% in 2022, 9.2% in 2023, 8.9% in 2024 and 2.6% in 2025.

Profit in 2025 fell even as revenue grew, which points to higher cost pressure. The company attributed the third-quarter 2025 pressure to sample costs, new product development and initial market-entry marketing spending, which it described as temporary (reported in November 2025).

Net profit attributable to shareholders peaked at KRW 28.1 billion in 2024, up 92.1%, and fell to KRW 7.38 billion in 2025, down 73.7%. Net profit including non-controlling interests was KRW 7.16 billion in 2025, a different figure.

Quarterly results moved sharply: the fourth quarter of 2025 posted an operating loss of KRW 6.51 billion and a net loss attributable to shareholders of KRW 7.32 billion.

The first quarter of 2026 returned to profit with operating profit of KRW 1.32 billion, the second quarter swung back to an operating loss of KRW 1.9 billion, and the third quarter of 2026 recorded operating profit of KRW 3.42 billion, up 312.5% from a year earlier.

The third-quarter net loss attributable to shareholders widened to KRW 4.4 billion, so operating profit and shareholder net income pointed in different directions. The loss over the last four quarters totaled KRW 10.7 billion.

05

Industry analysis

Synopex's main end market is smartphones. Because FPCB connects internal smartphone components, a high FPCB revenue share ties results closely to smartphone demand. EV battery FPCB is at an early stage of market opening, with mass supply expected from 2027 after field testing in 2026, according to securities analysts.

A November 2025 report expected mass production by the end of 2026, but later coverage points to 2027, suggesting the timeline moved back a year.

Semiconductor chemical filters localize nano-grade filters that were previously imported, and certification by domestic chipmakers including Samsung Electronics will determine the outcome.

The dialysis market is driven by demand for hemodialysis as populations age, and NH Investment & Securities expects faster substitution of imported products given a broader lineup and clinical results.

In water treatment, the Lotte Chemical water business acquisition gives Synopex coverage across purification, wastewater, reuse and desalination. Within the chemical sector, Synopex operates closer to a specialty materials and components business centered on filters and membranes than to commodity petrochemicals.

06

Outlook

Several confirmed milestones are on the company's agenda. In July 2026 it announced a KRW 15 billion investment in EV FPCB module equipment, and sample testing with two global customers for EV FPCB is in progress with mass supply expected in 2027.

The 10-nanometer chemical filter is in customer testing, while the 5-nanometer product remains in development.

In dialysis, the first export shipment of domestically produced hemodialysis filters occurred in April 2026, the HD product received approval in August 2026, and a portable RO water purifier was first supplied to Kyung Hee University Hospital in October 2026.

The company holds approvals for 11 hemodialysis filter types. Among brokerage estimates, NH Investment & Securities in a January 2026 report projected 2026 revenue of KRW 285.4 billion and operating profit of KRW 25 billion, and 2027 revenue of KRW 360 billion and operating profit of KRW 40.3 billion.

Reaching the 2026 projection would require a sharp rise in fourth-quarter revenue compared with the third quarter, so whether it is met is the next checkpoint. A May 2026 analysis by SangSang Securities expected new businesses to enter a full revenue growth phase from 2027. The company disclosed a corporate value enhancement plan notice on October 1, 2026.

07

Valuation

PER
—
PBR
1.9×
ROE
-6.3%
EPS
-₩125
BPS
₩1,817
Dividend per share
₩0

The cumulative net loss attributable to shareholders over the last four quarters reached KRW 10.7 billion, so PER cannot be calculated on an earnings basis. Earnings-based multiples were available when 2024 profit was positive, but the decline in profit after 2025 removed that reference.

Operating profit was positive in the third quarter of 2026, yet a net loss attributable to shareholders remained, so valuation reads differ between the operating and bottom-line levels. On an asset basis, the price-to-book ratio sits above 1x, meaning expectations for new businesses are priced above book value.

Shareholders' equity attributable to the parent was KRW 171.9 billion at the end of 2025, and total equity was KRW 171.7 billion. Cash dividend yield is effectively low, and the company has returned value through bonus issues linked to dividends, at 0.05 new shares per common share announced in November 2025. The key valuation question is whether earnings recovery and the timing of new-business revenue line up.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Regulatory approvals and shipments are accumulating

The HD product received approval from the Ministry of Food and Drug Safety in August 2026, and the first export shipment of domestically produced hemodialysis filters occurred in April 2026. The company holds approvals for 11 filter types, and adoption by university and general hospitals is expanding. A 30% domestic share target by 2029 gives a defined path for revenue contribution.

Localization of semiconductor chemical filters

Synopex localized 10-nanometer chemical filters and is running quality tests for Samsung Electronics certification. Securities analysts have said supply to Samsung Electronics and SK hynix could be possible once certification is complete. Because the product replaces imports, passing certification could create a new revenue contribution.

Water treatment portfolio and EV FPCB readiness

The Lotte Chemical water business acquisition gives Synopex a portfolio across purification, wastewater, reuse and desalination. The Yen Fong plant in Vietnam completed an integrated process for EV FPCB, and a KRW 15 billion equipment investment was announced in July 2026. Facility preparation is aligned with mass supply planned for 2027.

09

Bear factors

Concentration in smartphone FPCB customers

FPCB generated 89.5% of revenue in 2025, and about 90% of that is for smartphones. Samsung Electronics accounts for an outsized share of smartphone revenue, so results depend on customer volumes and product cycles. Until new businesses scale, this concentration remains a main source of earnings volatility.

Weaker earnings and the gap between operating and net profit

The operating margin fell to 2.6% in 2025 from 9.2% in 2023. Operating profit was KRW 3.42 billion in the third quarter of 2026, but the net loss attributable to shareholders was KRW 4.4 billion. The cumulative loss over the last four quarters reached KRW 10.7 billion, so profitable quarters did not offset the losses.

Risk that new-business revenue is delayed

The EV FPCB mass-production timing appears to have shifted from the end of 2026 in a November 2025 report to 2027 in later coverage. Semiconductor filter certification at Samsung Electronics is not complete, and the 5-nanometer product is still in development.

Reaching the 2026 revenue projection would require a large fourth-quarter increase, leaving a wide gap between forecast and results.

10

Risk factors

Customer and business structure

A high FPCB revenue share makes results sensitive to smartphone demand and changes in volumes from specific customers. If the end-product cycle weakens, the revenue base could be hit before new businesses take hold. The pace of diversification is the condition that would ease this risk.

Development, certification and costs

Sample costs and qualification-test expenses were cited as a major cause of the operating profit decline in the third quarter of 2025. If Samsung Electronics certification for the semiconductor filter or customer testing for EV FPCB is delayed, the cost burden could last longer than revenue gains. Certification outcomes and the trend in sample costs are the points to monitor.

Financial and governance matters

The debt-to-equity ratio rose from 40.4% in 2024 to 51.1% in 2025. In July 2026 the company filed a corrected disclosure on a share pledge agreement that involves a change in the largest shareholder. Governance changes can affect management continuity and investment plans, so follow-up disclosures need monitoring.

11

What to watch next

  1. Mid-March 2027

    Annual report for 2026. The fourth quarter of 2026 enters the disclosed results, and it becomes possible to compare full-year revenue against the 2026 projection from NH Investment & Securities.

  2. Mid-May 2027

    First-quarter 2027 results, based on the precedent of the first-quarter 2026 release on May 15. Key points are whether operating profit stays positive and how much new-business revenue is reflected.

  3. 2027 (timing to be confirmed)

    Whether EV FPCB mass supply begins. Whether production starts after 2026 field testing is the indicator that determines the timing of new-business revenue.

  4. Timing of Samsung Electronics certification (to be determined)

    Whether the 10-nanometer semiconductor chemical filter passes certification. Passing would mark the start of semiconductor materials revenue, while a delay would extend the cost burden.

  5. 2029

    Target year for a 30% domestic share in hemodialysis filters. Hospital adoption after approval will show the path toward this target.

12

Overall view

Synopex's disclosed results show profitability declining after the 2023 operating profit peak. Revenue rose to KRW 261.5 billion in 2025, but operating profit reached only KRW 6.76 billion.

Quarterly results in 2026 moved from a first-quarter profit to a second-quarter loss and a third-quarter operating profit, and the net loss attributable to shareholders continued for two consecutive quarters.

On the strength side, dialysis product approval and first exports, localization of semiconductor chemical filters, and expected EV FPCB mass supply in 2027 support the diversification case.

On the weakness side, FPCB's 89.5% revenue share keeps customer concentration high, new-business revenue has been pushed toward 2027 or later, and the cumulative net loss attributable to shareholders over the last four quarters was KRW 10.7 billion.

Because earnings-based multiples cannot be calculated, valuation can only be described against book value and expectations for new businesses.

The next checkpoints are whether the gap between operating profit and net profit attributable to shareholders narrows in the fourth quarter reported in the 2026 annual report, and how much new-business revenue appears in the first-quarter 2027 results. This report is for information only and does not include an investment opinion or target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. synopex.com
  2. comp.wisereport.co.kr
  3. synopex.com
  4. dealsite.co.kr
  5. dailyinvest.kr
  6. v.daum.net
  7. dealsite.co.kr
  8. etoday.co.kr
  9. synopex.irpage.co.kr
  10. buffettlab.co.kr
  11. m.irgo.co.kr
  12. m.thinkpool.com
  13. m.etoday.co.kr
  14. factchart.co.kr
  15. indexbox.io
  16. finance.yahoo.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis